Outlook Therapeutics, Inc.
OTLKOutlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of the first approved ophthalmic formulation of bevacizumab for retinal diseases.
Earnings
Next report
Date not yet announcedCompetitors
By market cap
By revenue growth
Profile
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of the first approved ophthalmic formulation of bevacizumab for retinal diseases. Its lead product, ONS-5010/LYTENAVA, is designed to treat wet age-related macular degeneration (wet AMD) as a regulated alternative to the common off-label use of repackaged intravenous bevacizumab. The company aims to capture significant market share in the global anti-VEGF retina market by providing a standardized, approved therapeutic option.
The company holds the first and only marketing authorization for an ophthalmic bevacizumab formulation in the EU and UK, positioning it as a regulated alternative to off-label repackaged cancer drugs.
FAQ
- What is Outlook Therapeutics, Inc.'s market cap?
- Outlook Therapeutics, Inc. (OTLK) has a market capitalization of $164.8M and trades on NASDAQ.
- Who are Outlook Therapeutics, Inc.'s competitors?
- Outlook Therapeutics, Inc.'s key competitors include Regeneron Pharmaceuticals, Lineage Cell Therapeutics, Inc., Harrow, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Outlook Therapeutics, Inc. partner with?
- Outlook Therapeutics, Inc.'s notable partners include European Commission, Medicines and Healthcare products Regulatory Agency.
- Where is Outlook Therapeutics, Inc. headquartered?
- Outlook Therapeutics, Inc. is headquartered in United States of America and employs approximately 24 people. It has been publicly traded since 2016.